Abstract:Integrin alpha(v)beta(6) is overexpressed in a variety of cancers, and its expression is often associated with poor prognosis. Therefore, there is a need to develop affinity reagents for noninvasive imaging of integrin alpha(v)beta(6) expression since it may provide early cancer diagnosis, more accurate prognosis, and better treatment planning. We recently engineered and validated highly stable cystine knot peptides that selectively bind integrin alpha(v)beta(6) with no cross-reactivity to integrins alpha(v)beta(5), alpha(5)beta(1), or alpha(v)beta(3), also known to be overexpressed in many cancers. Here, we developed a single photon emission computed tomography (SPECT) probe for imaging integrin alpha(v)beta(6) positive tumors. Cystine knot peptide, S(0)2, was first conjugated with a single amino acid chelate (SAAC) and labeled with [Tc-99m(H2O)(3)(CO)(3)](+). The resulting probe, Tc-99m-SAAC-S(0)2, was then evaluated by in vitro cell uptake studies using two alpha(v)beta(6) positive cell lines (human lung adenocarcinoma cell line HCC4006 and pancreatic cancer cell line BxPC-3) and two alpha(v)beta(6) negative cell lines (human lung adenocarcinoma cell line H838 and human embryonic kidney cell line 293T). Next, SPECT/CT and biodistribution studies were performed in nude mice bearing HCC4006 and H838 tumor xenografts to evaluate the in vivo performance of Tc-99m-SAAC-S(0)2. Significant differences in the uptake of Tc-99m-SAAC-S(0)2 were observed in alpha(v)beta(6) positive vs negative cells (P < 0.05). Biodistribution and small animal SPECT/CT studies revealed that Tc-99m-SAAC-S(0)2 accumulated to moderate levels in antigen positive tumors (similar to 2% ID/g at 1 and 6 h postinjection, n = 3 or 4/group). Moreover, the probe demonstrated tumor-to-background tissue ratios of 6.81 +/- 2.32 (tumor-to-muscle) and 1.63 +/- 0.18 (tumor-to-blood) at 6 h postinjection in alpha(v)beta(6) positive tumor xenografts. Co-incubation of the probe with excess amount of unlabeled S(0)2 as a blocking agent demonstrated significantly reduced tumor uptake, which is consistent with specific binding to the target. Renal filtration was the main route of clearance. In conclusion, knottin peptides are excellent scaffolds for which to develop highly stable imaging probes for a variety of oncological targets. Tc-99m-SAAC-S(0)2 demonstrates promise for use as a SPECT agent to image integrin alpha(v)beta(6) expression in living systems.

Integrin Αvβ6–targeted SPECT Imaging for Pancreatic Cancer Detection

Integrin Alpha(V)Beta(6)-Targeted Spect Imaging for Pancreatic Cancer Detection

Small-animal SPECT/CT Imaging of Cancer Xenografts and Pulmonary Fibrosis Using a 99m Tc-labeled Integrin Αvβ6-Targeting Cyclic Peptide with Improved in Vivo Stability

Integrin Α6 Targeted Near Infrared Fluorescent Imaging and Photoacoustic Imaging of Hepatocellular Carcinoma in Mice

An Integrin-αvβ6/α5β1-Bitargeted Probe for the SPECT Imaging of Pancreatic Adenocarcinoma in Preclinical and Primary Clinical Studies.

99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.

Tc-99m-Labeled Cystine Knot Peptide Targeting Integrin Alpha(V)Beta(6) For Tumor Spect Imaging

Integrin Α6-Targeted Positron Emission Tomography Imaging of Colorectal Cancer

Clinical Translation of a 68Ga-Labeled Integrin Αvβ6–targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer

An Integrin Alpha 6-Targeted Radiotracer with Improved Receptor Binding Affinity and Tumor Uptake

A Near-Infrared Phthalocyanine Dye-Labeled Agent for Integrin Alpha V Beta 6-Targeted Theranostics of Pancreatic Cancer

Evaluation of a 99Mtc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin Αvβ3-Positive Breast Cancer

Development and Preclinical Evaluation of a Cyclic PET Tracer Targeting Integrin-Α6 on Colorectal Cancer Models

99Mtc-3P-rgd2 Micro-Single-Photon Emission Computed Tomography/Computed Tomography Provides a Rational Basis for Integrin Αvβ3-Targeted Therapy

Imaging a Pancreatic Carcinoma Xenograft Model with 11C-Acetate: a Comparison Study with 18F-FDG

A Ga-68 Labeled Peptide for Imaging of {alpha}v{beta}6 Positive Tumor

Potential Efficacy of 68 Ga-Trivehexin PET/CT and Immunohistochemical Validation of αvβ6 Integrin Expression in Patients With Head and Neck Squamous Cell Carcinoma and Pancreatic Ductal Adenocarcinoma

Integrin αvβ6-targeted MR molecular imaging of breast cancer in a xenograft mouse model

Integrin Α6 Targeted Positron Emission Tomography Imaging of Hepatocellular Carcinoma in Mouse Models.

A Cystine Knot Peptide Targeting Integrin αvβ6 for Photoacoustic and Fluorescence Imaging of Tumors in Living Subjects

First-in-human Pilot Study of an Integrin Α6-Targeted Radiotracer for SPECT Imaging of Breast Cancer